1490 related articles for article (PubMed ID: 15789122)
1. Cellular processing of platinum anticancer drugs.
Wang D; Lippard SJ
Nat Rev Drug Discov; 2005 Apr; 4(4):307-20. PubMed ID: 15789122
[TBL] [Abstract][Full Text] [Related]
2. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
Reardon JT; Vaisman A; Chaney SG; Sancar A
Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin: mechanism of action and antineoplastic activity.
Raymond E; Faivre S; Woynarowski JM; Chaney SG
Semin Oncol; 1998 Apr; 25(2 Suppl 5):4-12. PubMed ID: 9609103
[TBL] [Abstract][Full Text] [Related]
4. Analysis of cytotoxicities of platinum compounds.
Goodisman J; Hagrman D; Tacka KA; Souid AK
Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
[TBL] [Abstract][Full Text] [Related]
5. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
Kelland LR; Sharp SY; O'Neill CF; Raynaud FI; Beale PJ; Judson IR
J Inorg Biochem; 1999 Oct; 77(1-2):111-5. PubMed ID: 10626362
[TBL] [Abstract][Full Text] [Related]
6. Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes.
Ahmad S
Chem Biodivers; 2010 Mar; 7(3):543-66. PubMed ID: 20232326
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin and platinum drugs at the molecular level. (Review).
Boulikas T; Vougiouka M
Oncol Rep; 2003; 10(6):1663-82. PubMed ID: 14534679
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxicity, DNA strand breakage and DNA-protein crosslinking by a novel transplatinum compound in human A2780 ovarian and MCF-7 breast carcinoma cells.
Farrell N; Povirk LF; Dange Y; DeMasters G; Gupta MS; Kohlhagen G; Khan QA; Pommier Y; Gewirtz DA
Biochem Pharmacol; 2004 Sep; 68(5):857-66. PubMed ID: 15294448
[TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of dichloro-bis(pyrazole)palladium(II) and dichloro-bis(pyrazole)platinum(II) complexes as anticancer agents.
Keter FK; Kanyanda S; Lyantagaye SS; Darkwa J; Rees DJ; Meyer M
Cancer Chemother Pharmacol; 2008 Dec; 63(1):127-38. PubMed ID: 18350297
[TBL] [Abstract][Full Text] [Related]
10. Characterization of oxaliplatin-DNA adduct formation in DNA and differentiation of cancer cell drug sensitivity at microdose concentrations.
Hah SS; Sumbad RA; de Vere White RW; Turteltaub KW; Henderson PT
Chem Res Toxicol; 2007 Dec; 20(12):1745-51. PubMed ID: 18001055
[TBL] [Abstract][Full Text] [Related]
11. Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cellular uptake in colorectal cancer cell lines.
Virag P; Perde-Schrepler M; Fischer-Fodor E; Tatomir C; Dorneanu SA; Cernea VI; Irimie A
Anticancer Drugs; 2012 Nov; 23(10):1032-8. PubMed ID: 22614106
[TBL] [Abstract][Full Text] [Related]
12. New platinum(II) complexes containing both an O,O'-chelated acetylacetonate ligand and a sulfur ligand in the platinum coordination sphere induce apoptosis in HeLa cervical carcinoma cells.
Muscella A; Calabriso N; De Pascali SA; Urso L; Ciccarese A; Fanizzi FP; Migoni D; Marsigliante S
Biochem Pharmacol; 2007 Jun; 74(1):28-40. PubMed ID: 17481588
[TBL] [Abstract][Full Text] [Related]
13. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.
Garmann D; Warnecke A; Kalayda GV; Kratz F; Jaehde U
J Control Release; 2008 Oct; 131(2):100-6. PubMed ID: 18691617
[TBL] [Abstract][Full Text] [Related]
14. In vitro biochemical and pharmacological evaluation of a novel cytotoxic dinuclear platinum(II) complex with 3-amino-5-methyl-5-phenylhydantoin.
Momekov GTs; Ugrinova I; Pasheva EA; Bakalova AG; Varbanov HP; Ferdinandov DV; Ivanov DS; Konstantinov SM
Ann N Y Acad Sci; 2009 Aug; 1171():649-58. PubMed ID: 19723116
[TBL] [Abstract][Full Text] [Related]
15. DNA damage-processing pathways involved in the eukaryotic cellular response to anticancer DNA cross-linking drugs.
Beljanski V; Marzilli LG; Doetsch PW
Mol Pharmacol; 2004 Jun; 65(6):1496-506. PubMed ID: 15155842
[TBL] [Abstract][Full Text] [Related]
16. Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations.
Fojo T; Farrell N; Ortuzar W; Tanimura H; Weinstein J; Myers TG
Crit Rev Oncol Hematol; 2005 Jan; 53(1):25-34. PubMed ID: 15607933
[TBL] [Abstract][Full Text] [Related]
17. Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity.
Saldivar JS; Wu X; Follen M; Gershenson D
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S56-71. PubMed ID: 17884153
[TBL] [Abstract][Full Text] [Related]
18. Anticancer activity of a series of platinum complexes integrating demethylcantharidin with isomers of 1,2-diaminocyclohexane.
Yu CW; Li KK; Pang SK; Au-Yeung SC; Ho YP
Bioorg Med Chem Lett; 2006 Mar; 16(6):1686-91. PubMed ID: 16386904
[TBL] [Abstract][Full Text] [Related]
19. Differential processing of antitumour-active and antitumour-inactive trans platinum compounds by SKOV-3 ovarian cancer cells.
Boccarelli A; Giordano D; Natile G; Coluccia M
Biochem Pharmacol; 2006 Jul; 72(3):280-92. PubMed ID: 16765322
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells.
Luo FR; Wyrick SD; Chaney SG
Oncol Res; 1998; 10(11-12):595-603. PubMed ID: 10367941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]